Article
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.
Cancer cell - 9 Mar 2015
Sharpe Hayley J, Pau Gregoire, Dijkgraaf Gerrit J, Basset-Seguin Nicole, Modrusan Zora, Januario Thomas, Tsui Vickie, Durham Alison B, Dlugosz Andrzej A, Haverty Peter M, Bourgon Richard, Tang Jean Y, Sarin Kavita Y, Dirix Luc, Fisher David C, Rudin Charles M, Sofen Howard, Migden Michael R, Yauch Robert L, de Sauvage Frederic J
Abstract excerpt
Smoothened (SMO) inhibitors are under clinical investigation for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). Most BCC patients experience significant clinical benefit on vismodegib, but some develop resistance. Genomic analysis of tumor biopsies revealed that vismodegib resistance is associated with Hedgehog (Hh) pathway...
Topics
- Anilides
- Binding Sites
- Carcinoma, Basal Cell
- DNA Copy Number Variations
- DNA Mutational Analysis
- Drug Resistance, Neoplasm
- Exome
- Hedgehog Proteins
- Humans